News

The Financial Express56m
Is the Halol hurdle too high for Sun Pharma? 4 reasons why Nomura sees limited upside potential
Sun Pharma's Halol issues limit potential; Nomura sees a 17% upside. Stay updated on regulatory developments at Halol ...